Emerging therapy for diabetic neuropathy: Cell therapy targeting vessels and nerves

Hyongbum Kim, Julie J. Kim, Youngsup Yoon

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Diabetic neuropathy (DN), the most common complication of diabetes, frequently leads to foot ulcers and may progress to limb amputations. Despite continuous increase in incidence, there is no clinical therapy to effectively treat DN. Pathogenetically, DN is characterized by reduced vascularity in peripheral nerves and deficiency in angiogenic and neurotrophic factors. We will briefly review the pathogenetic mechanism of DN and address the effects and the mechanisms of cell therapies for DN. To reverse the changes of DN, studies have attempted to deliver neurotrophic or angiogenic factors for treatment in the form of protein or gene therapy; however, the effects turned out to be very modest if not ineffective. Recent studies have demonstrated that bone marrow (BM)-derived cells such as mononuclear cells or endothelial progenitor cells (EPCs) can effectively treat various cardiovascular diseases through their paracrine effects. As BM-derived cells include multiple angiogenic and neurotrophic cytokines, these cells were used for treating experimental DN and found to reverse manifestations of DN. Particularly, EPCs were shown to exert favorable therapeutic effects through enhanced neural neovascularization and neuro-protective effects. These findings clearly indicate that DN is a complex disorder with pathogenetic involvement of both vascular and neural components. Studies have shown that cell therapies targeting both vascular and neural elements are shown to be advantageous in treating DN.

Original languageEnglish
Pages (from-to)168-178
Number of pages11
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
Volume12
Issue number2
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Diabetic Neuropathies
Cell- and Tissue-Based Therapy
Therapeutics
Angiogenesis Inducing Agents
Nerve Growth Factors
Bone Marrow Cells
Blood Vessels
Foot Ulcer
Therapeutic Uses
Diabetes Complications
Peripheral Nerves
Amputation
Genetic Therapy
Cardiovascular Diseases
Extremities
Cytokines

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

@article{49cd687766ed4ac3bb1e3f0aed29faf5,
title = "Emerging therapy for diabetic neuropathy: Cell therapy targeting vessels and nerves",
abstract = "Diabetic neuropathy (DN), the most common complication of diabetes, frequently leads to foot ulcers and may progress to limb amputations. Despite continuous increase in incidence, there is no clinical therapy to effectively treat DN. Pathogenetically, DN is characterized by reduced vascularity in peripheral nerves and deficiency in angiogenic and neurotrophic factors. We will briefly review the pathogenetic mechanism of DN and address the effects and the mechanisms of cell therapies for DN. To reverse the changes of DN, studies have attempted to deliver neurotrophic or angiogenic factors for treatment in the form of protein or gene therapy; however, the effects turned out to be very modest if not ineffective. Recent studies have demonstrated that bone marrow (BM)-derived cells such as mononuclear cells or endothelial progenitor cells (EPCs) can effectively treat various cardiovascular diseases through their paracrine effects. As BM-derived cells include multiple angiogenic and neurotrophic cytokines, these cells were used for treating experimental DN and found to reverse manifestations of DN. Particularly, EPCs were shown to exert favorable therapeutic effects through enhanced neural neovascularization and neuro-protective effects. These findings clearly indicate that DN is a complex disorder with pathogenetic involvement of both vascular and neural components. Studies have shown that cell therapies targeting both vascular and neural elements are shown to be advantageous in treating DN.",
author = "Hyongbum Kim and Kim, {Julie J.} and Youngsup Yoon",
year = "2012",
month = "6",
day = "1",
doi = "10.2174/187153012800493486",
language = "English",
volume = "12",
pages = "168--178",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

Emerging therapy for diabetic neuropathy : Cell therapy targeting vessels and nerves. / Kim, Hyongbum; Kim, Julie J.; Yoon, Youngsup.

In: Endocrine, Metabolic and Immune Disorders - Drug Targets, Vol. 12, No. 2, 01.06.2012, p. 168-178.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Emerging therapy for diabetic neuropathy

T2 - Cell therapy targeting vessels and nerves

AU - Kim, Hyongbum

AU - Kim, Julie J.

AU - Yoon, Youngsup

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Diabetic neuropathy (DN), the most common complication of diabetes, frequently leads to foot ulcers and may progress to limb amputations. Despite continuous increase in incidence, there is no clinical therapy to effectively treat DN. Pathogenetically, DN is characterized by reduced vascularity in peripheral nerves and deficiency in angiogenic and neurotrophic factors. We will briefly review the pathogenetic mechanism of DN and address the effects and the mechanisms of cell therapies for DN. To reverse the changes of DN, studies have attempted to deliver neurotrophic or angiogenic factors for treatment in the form of protein or gene therapy; however, the effects turned out to be very modest if not ineffective. Recent studies have demonstrated that bone marrow (BM)-derived cells such as mononuclear cells or endothelial progenitor cells (EPCs) can effectively treat various cardiovascular diseases through their paracrine effects. As BM-derived cells include multiple angiogenic and neurotrophic cytokines, these cells were used for treating experimental DN and found to reverse manifestations of DN. Particularly, EPCs were shown to exert favorable therapeutic effects through enhanced neural neovascularization and neuro-protective effects. These findings clearly indicate that DN is a complex disorder with pathogenetic involvement of both vascular and neural components. Studies have shown that cell therapies targeting both vascular and neural elements are shown to be advantageous in treating DN.

AB - Diabetic neuropathy (DN), the most common complication of diabetes, frequently leads to foot ulcers and may progress to limb amputations. Despite continuous increase in incidence, there is no clinical therapy to effectively treat DN. Pathogenetically, DN is characterized by reduced vascularity in peripheral nerves and deficiency in angiogenic and neurotrophic factors. We will briefly review the pathogenetic mechanism of DN and address the effects and the mechanisms of cell therapies for DN. To reverse the changes of DN, studies have attempted to deliver neurotrophic or angiogenic factors for treatment in the form of protein or gene therapy; however, the effects turned out to be very modest if not ineffective. Recent studies have demonstrated that bone marrow (BM)-derived cells such as mononuclear cells or endothelial progenitor cells (EPCs) can effectively treat various cardiovascular diseases through their paracrine effects. As BM-derived cells include multiple angiogenic and neurotrophic cytokines, these cells were used for treating experimental DN and found to reverse manifestations of DN. Particularly, EPCs were shown to exert favorable therapeutic effects through enhanced neural neovascularization and neuro-protective effects. These findings clearly indicate that DN is a complex disorder with pathogenetic involvement of both vascular and neural components. Studies have shown that cell therapies targeting both vascular and neural elements are shown to be advantageous in treating DN.

UR - http://www.scopus.com/inward/record.url?scp=84861118805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861118805&partnerID=8YFLogxK

U2 - 10.2174/187153012800493486

DO - 10.2174/187153012800493486

M3 - Review article

C2 - 22236028

AN - SCOPUS:84861118805

VL - 12

SP - 168

EP - 178

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

IS - 2

ER -